ROCHESTER, N.Y., Oct. 8, 2009 (GLOBE NEWSWIRE) -- NaturalNano, Inc. (OTCBB:NNAN) (Frankfurt:N3N) Acting CEO and President James Wemett announced today that the series of Cornell's feasibility studies using Halloysite Natural Tubes has been very successful. This has been initiated under the direction of Professor Michael King, Ph.D. of the Department of Biomedical Engineering at Cornell University in Ithaca, New York and in co-operation with CellTraffix Inc.
Dr. King states, "NaturalNano's proprietary Halloysite nanotubes have enhanced the cell adhesion of circulating cancer cells to reactive surfaces and are found to be non toxic to the cells. The Halloysite significantly decreased the rolling velocity and increased the number of cancer cells captured using these Natural Tubes."
Wemett said, "These results are very exciting to NaturalNano. We are continuing to work with Cornell and the Research Lab of Dr. King."
"The success of the combination of Halloysite nanotubes and Dr. King's technology significantly advances our progress in developing our device used commercially to isolate stem or certain cancer cells," said Thomas Fitzgerald, CEO of CellTraffix, which is commercializing the research done by Dr. King and his team.
About NaturalNano, Inc.
NaturalNano, Inc. (OTCBB:NNAN) (Frankfurt:N3N) is a materials science company focused on developing and commercializing advanced nanocomposites. Based in Rochester, NY, the Company is focused on additive technologies and processes, including its proprietary Pleximer polymer additive, that add value to industrial polymers, plastics and composites, as well as consumer and industrial products. NaturalNano holds and licenses over 25 patents and applications, as well as proprietary know-how for extraction and separation processes, compositions, and derivatives of Halloysite and other nanotubes. Visit www.naturalnano.com for more information.
About CellTraffix Inc.
CellTraffix employs its unique understanding of the mechanics of cellular flow and cell trafficking in the blood stream to develop a range of proprietary medical devices. These are based on the CellSelect technology ranging from simple, low cost research tools for the separation and collection of cells in blood, to sophisticated in vivo and ex vivo therapeutic delivery systems and diagnostics to address a number of unmet medical needs relating to cancer, adult stem cells and immune cells. Visit www.celltraffix.com for more information.
Cautionary Statement Regarding Forward-Looking Statements: This press release may contain forward-looking statements regarding future events and future performance of NaturalNano that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano's filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-KSB and quarterly reports on Form 10-QSB filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports to the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.